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Abstract
Background: Numerous functional studies have shown that nitrergic neurotransmission plays a central role in peristalsis
and sphincter relaxation throughout the gut and impaired nitrergic neurotransmission has been implicated in clinical
disorders of all parts of the gut. However, the role of nitric oxide (NO) as a neurotransmitter continues to be controversial
because: 1) the cellular site of production during neurotransmission is not well established; 2) NO may interacts with other
inhibitory neurotransmitter candidates, making it difficult to understand its precise role.
Methodology/Principal Findings: Imaging NO can help resolve many of the controversies regarding the role of NO in
nitrergic neurotransmission. Imaging of NO and its cellular site of production is now possible. NO forms quantifiable
fluorescent compound with diaminofluorescein (DAF) and allows imaging of NO with good specificity and sensitivity in
living cells. In this report we describe visualization and regulation of NO and calcium (Ca
2+) in the myenteric nerve
varicosities during neurotransmission using multiphoton microscopy. Our results in mice gastric muscle strips provide visual
proof that NO is produced de novo in the nitrergic nerve varicosities upon nonadrenergic noncholinergic (NANC) nerve
stimulation. These studies show that NO is a neurotransmitter rather than a mediator. Changes in NO production in
response to various pharmacological treatments correlated well with changes in slow inhibitory junction potential of
smooth muscles.
Conclusions/Significance: Dual imaging and electrophysiologic studies provide visual proof that during nitrergic
neurotransmission NO is produced in the nerve terminals. Such studies may help define whether NO production or its
signaling pathway is responsible for impaired nitrergic neurotransmission in pathological states.
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Introduction
Nitric oxide (NO) has been proposed as a neuromuscular
neurotransmitter of nonadrenergic noncholinergic (NANC) inhib-
itory nerves in the parasympathetic [1] and the enteric nervous
systems [2]. Clinical importance of this signaling pathway is
evidenced by the fact that animal models of impaired nitrergic
neurotransmission reveal phenotypes resembling major human
gastrointestinal motility disorders [3–7]. However, because of the
unusual characteristics of NO, its status as a neurotransmitter or its
regulation remains unsettled.
While there is strong physiological evidence that NO is involved
in inhibitory neurotransmission [8–9], its role as a true
neurotransmitter has been questioned. It has been argued that
NO may a mediator of another neurotransmitter such as VIP [10–
11]. This later view is supported by biochemical studies in the
isolated postjunctional smooth muscle cells showing that VIP
generates NO in the smooth muscles [12]. However, in a critical
review of the available evidence, Van Geldre and Lefebvre [11]
concluded that VIP-generated NO in the isolated smooth muscles
may be nonphysiological. Based on electrophysiological studies, it
has been proposed that during nitrergic neurotransmission, NO is
generated in the nerves and is a true inhibitory neurotransmitter
[13–14].
NO has a unique chemistry. It reacts with 4,5-diaminofluor-
escein (DAF-2) to produce quantifiable fluorescent product DAF-2
triazole (DAF-2T). Reaction of NO with DAF-2 is highly specific
and sensitive (NO detection limit of 5 nM) [15–19] and can be
simultaneously imaged with Ca
2+ [20]. DAF-2 is not toxic to living
cells and does not impair cellular function [17–18]. Imaging
performed with a multiphoton microscopy [20–22] can visualize
the myenteric nerve varicosities and other structures, including
smooth muscle cells, at deeper levels below the surface.
The purpose of the present studies was to examine the effect of
electricalfieldstimulationofmicegastricmusclestrips:1)onNOand
Ca
2+ signals at the cellular level by fluorescent imaging; 2) on the
effect of pharmacological treatments on these signals; 3) on nitrergic
slow inhibitory junction potential (sIJP) in electrophysiological
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e4990studies; and 4) to compare the effects of the pharmacological
treatments on NO in the imaging studies and sIJP in the
electrophysiological studies.
These results provide, for the first time, visual identification
of nerve varicosities in situ in the gut and also provides proof
that on NANC nerve stimulation, NO is produced in the
myenteric nitrergic nerve varicosities and not in the smooth
muscle cells, thereby demonstrating that NO is a neurotrans-
mitter rather than a mediator produced in the smooth muscles.
They also document that during neurotransmission NO is
produced de novo and not stored as a NO donor in the
varicosities and released with other classical neurotransmitters.
Changes in NO production in response to various pharmaco-
logical treatments correlated well with changes in slow
inhibitory junction potential of smooth muscles. Functional
studies combined with imaging may help elucidate whether NO
production or its upstream or downstream signaling is the
underlying mechanisms of impaired nitrergic neurotransmission
in the pathological states.
Results and Discussion
Visualization of myenteric nerve varicosities by their Ca
2+
signals
We first sought to visualize varicosities of myenteric neurons in
the mouse gastric smooth muscle. Imaging was focused on the
varicosities because they are the sites of release of the
neurotransmitters. Multiphoton imaging of circular muscle strips
preloaded with the calcium indicator after EFS revealed discrete
orange-red fluorescent spots. These images were superimposed on
image of smooth muscles obtained in the transmission mode. Note
that varicosities were linearly oriented along the longitudinal axis
of the underlying muscle fibers (Figure 1). These fluorescent spots
were not seen in tissues pretreated with tetrodotoxin, suggesting
that they represented nerve varicosities. Figure 1a shows a low
power view of the varicosities visible against the background of the
non-fluorescent smooth muscle cells at a depth of 150 mm from the
surface of the strip. Varicosities appeared as pearl-like structures
that are linearly arranged along the axis of the underlying smooth
Figure 1. Visualization of myenteric nerve varicosities by their Ca
2+ signals. These studies were done after EFS of the muscle strips
preloaded with the indicator calcium orange. The fluorescent image was superimposed on the image in the transmission mode (a) is a low power
view fluorescent (orange-red) varicosities. Note the varicosities along the axon running in the long axis of the circular muscles. (b) is magnified view of
one of the axons with varicosities along its length . Downward pointing arrows show the varicosities and upward pointing arrows indicate the inter-
varicosity axon. (c) shows intensity profiles of the fluorescent varicosities. Note that there was no Ca
+ signal in smooth muscle cells.
doi:10.1371/journal.pone.0004990.g001
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conditions that blocked neural excitation of the smooth muscles.
Figure 1b shows a magnified view of an axon with the varicosities.
The varicosities varied somewhat in their size and were on an
average 2–4 mm62–3 mm and were separated from each other,
with inter-varicosity interval varying from 2 mm to greater than
200 mm. Figure 1c shows intensity (height) and width of localized
fluorescent calcium signals. These columns represent fluorescent
signals from the varicosities. This view also shows that the
varicosities are linearly arranged on an axon and are separated by
inter-varicosity intervals. Ca
2+ signals identify all nitrergic and
non-nitrergic varicosities. These studies show that multiphoton
microscopy can vividly visualize varicosities on axons deep below
the surface in intact tissue. Elevated Ca
2+ signals were not seen in
smooth muscles because EFS was applied under nonadrenergic
noncholinergic conditions to block muscle excitation.
Visualization of NO in the varicosities
To visualize nitrergic varicosities, we examined muscle strips
preloaded with DAF-2 after applying EFS under NANC
conditions. Green DAF-2T fluorescence represent NO signals
(Figure 2). Panel (2a) shows fluorescent green NO signals in
nitrergic varicosities superimposed on the underlying smooth
muscle layer imaged in the regular transmission mode. Note the
absence of NO signals in the smooth muscle cells. The neurally
released NO may diffuse into the postjunctional smooth muscles or
ICCs to exert its effects on these structures. However, no NO
signals were seen in the smooth muscles or ICCs, suggesting that
the level of NO in the target tissue was below the threshold of
detection and may have been consumed by its action on the target
enzymes.
We also examined NO signals in the strips preloaded with DAF-
2DA but not electrically stimulated, tissues that received electrical
stimulation and the tissue that were pretreated with L-NAME
prior to EFS. Panel (2b) shows intensity (height and width) of the
NO fluorescent signals from the varicosities. Note that very few
NO signals were seen in the strips without EFS. The signals
increased in the strips that received EFS and were again absent in
the strips that receive EFS after L-NAME treatment. Panel (2c)
shows relative quantification of the NO signals. The bar graphs
Figure 2. Visualization of NO signals in the varicosities. These studies were done after EFS of the muscle strips preloaded with NO indicator
DAF-2. (a) is a low power view showing the superimposed NO fluorescent image and the image in the transmission mode. Note the green fluorescent
varicosities seen along axons running in the long axis of smooth muscles. Also note that there were no NO signals in the smooth muscles. (b)
Represents examples of intensity profiles of the NO signals in the unstimulated varicosities, the varicosities in the muscle strip stimulated with EFS
and a muscle strip that was treated with L-NAME prior to the stimulus. (c) Represents relative quantification of the NO signals. Note very small NO
signals in the unstimulated state and in stimulated state after L-NAME treatment.
doi:10.1371/journal.pone.0004990.g002
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(unstimulated strips), 4.060.97 after EFS, and 1.060.03 in strips
pretreated with NOS inhibitor, L-NAME (mean6SEM of
normalized fluorescence intensity in arbitrary units, n=6). Basal
levels of NO may be generated by the tonic activity of the nitrergic
neurons. These observations strongly suggest that the green signals
are truly due to NO produced in the nerve varicosities.
Colocalization of NO and Ca
2+ in the varicosities
In order to identify whether NO signals were produced in
prejunctional nitrergic nerve terminals that also showed Ca
2+
signals, we loaded the muscle strips with both DAF-2 and calcium
orange and applied EFS. These strips were imaged for NO and
Ca
2+ signals (Figure 3). Top panel shows green NO signals and
middle panel shows orange-red Ca
2+ in the varicosities. Bottom
panel shows yellow color of the colocalized Ca
2+ and NO signals.
Some varicosities showed only orange-red fluorescence without
yellow fluorescence; these may represent non-nitrergic varicosities.
Preliminary studies of serial 1 second imaging of calcium and NO
signals showed that Ca
2+ signal appeared within 1 second of EFS
and the NO signal followed it. Further dynamic studies using a
calcium dye with fast kinetics are needed to fully document
temporal relationship of the Ca
2+ and NO signals.
Colocalization of NO and nNOS in the varicosities
In order to identify whether NO signals were produced in
prejunctional nitrergic nerve terminals, we applied EFS to the
tissues that had been loaded with DAF-2. Since the reaction of
DAF-2 with NO is irreversible, the fluorescent DAF-2T marker
remained in the varicosities for a long time. These strips were then
immunostained with anti-nNOS antibody. The muscles strips with
DAF-2T marker and anti-nNOS staining were examined for
colocalized fluorescence. NO signals were colocalized to the nerve
terminals that showed immunoreactivity to nNOS, indicating that
NO production occurred in the nitrergic nerve varicosities
(Figure 4). These imaging studies provide visual proof that during
nitrergic neurotransmission, nitric oxide is produced de novo in the
nitrergic nerve varicosities. NO signals were not seen in the
smooth muscle cells.
Effect of various antagonists on Ca
2+ and NO signals in
the muscle strips
We also examined the effect of various known antagonists of
nitrergic neurotransmission on Ca
2+ and NO signals in the
electrically stimulated strips preloaded with DAF-2 and calcium
orange. Table 1 summarizes the relative quantification of NO and
Ca
2+ signals after various antagonist treatments. Note that EFS
(control) increased NO and Ca
2+ signals. The elevation of NO and
Ca
2+ signals were abolished by tetrodotoxin. Since tetrodotoxin
blocks the fast sodium channel that mediates the action potential
that is conducted along the axon and depolarizes the nerve
varicosities to cause Ca
2+ influx [11], these results suggest that the
EFS response was due to stimulation of cell bodies or fiber tracts
rather than direct stimulation of the varicosities. Effect of EFS was
blocked by the selective inhibitor of N-type Ca
2+ channels, v-
CTX GVIA, so that no significant increase in Ca
2+ or NO signals
were seen. However, L-type Ca
2+ channel blocker, nifedipine, did
not alter the increases in Ca
2+ or NO signals. These observations
indicate that Ca
2+ entry into the varicosities that stimulates NO
production occurred via N-type Ca
2+ channels. Pretreatment of
tissues with calmodulin (CaM) inhibitor W7 did not affect Ca
2+
increase, but markedly suppressed NO production by EFS ,
suggesting that increase in internal Ca
2+ stimulates nNOS via a
Ca
2+-CaM mediated process to produce NO. Similarly, pretreat-
ment with the nNOS inhibitor L-NAME suppressed NO signals
without affecting the Ca
2+ signals, showing that suppression of
nNOS caused suppression of NO generation in the presence of
normal increase in Ca
2+ upon electrical stimulation.
Effect of various antagonists on the slow IJPs in mice
gastric muscle strips
In order to correlate pharmacology of imaging studies with
functional neurophysiological studies of smooth muscle membrane
potentials, we examined the effects of antagonists on the nitrergic
slow inhibitory junction potentials (sIJP). EFS of muscle strips
under NANC conditions produced two overlapping IJPs called the
fast and the slow IJPs. Apamin treatment blocked fast IJP and
revealed the nitrergic slow IJP [13,14,23]. The slow IJP was
blocked by TTX, v-CTX GVIA as well as W7 and L-NAME, but
Figure 3. Colocalization of NO and Ca
2+ in the varicosities. The muscle strip simultaneously preloaded with calcium orange and DAF-2A were
electrically stimulated and the varicosities were examined for Ca
2+ and NO signals. Top panel shows green NO positive varicosities. Middle panel
shows orange-red calcium positive varicosities. Bottom panel shows colocalized NO and Ca
2+ signals. Neither NO nor Ca
2+signals were seen in the
neighboring smooth muscle cells. (3206magnification).
doi:10.1371/journal.pone.0004990.g003
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representative slow IJP and summarizes the quantitative data.
Bars represent mean values6SEM (6 cells, n=3 mice). These
results show that antagonists of physiologic nitrergic slow IJP also
suppress NO signals in the varicosities and these events can be
documented using the imaging studies.
Conclusions
In conclusion, the unique chemical properties of NO and its
indicator dyes and multiphoton microscopy allows imaging of NO
during nitrergic neurotransmission that is not possible with many
other neurotransmitters. These studies provide visual proof that
NO is a true neurotransmitter and not a secondary mediator.
Imaging of nitrergic neurotransmission may help distinguish
between disorders due to impaired NO production such as nNOS
deficiency and those due to impaired NO action such as seen in
deficiencies of NO sensitive guanylyl cyclase [4], cGMP kinase1
[5], Collagen XIXa1 [6] or c-kit [24]. Simultaneous NO and Ca
2+
imaging studies combined with neurophysiology may also provide
an important tool for understanding mechanisms of impaired
nitrergic neurotransmission in motor disorders of the gut. Such
studies may also help better define the underlying defect in
nitrergic neurotransmission in conditions such as diabetic
gastroparesis [7] and other human gastrointestinal diseases like
achalasia [6] and abnormal gastrointestinal motility due to
undefined cause. Simultaneous imaging of Ca
2+ and NO can also
help document whether the suppressed nitrergic neurotransmis-
sion is due to abnormalities in calcium kinetics, CaM abnormal-
ities or defects in the enzyme, nNOSa. Such studies may also be
helpful in elucidating abnormalities in urinary tract and cerebral
blood vessels where nitrergic neurotransmission is a major
regulatory mechanism.
Materials and Methods
Ethics Statement
The experimental protocol used was approved by the Animal
Care Committee of the VA Boston Healthcare System.
Animals and Tissue Preparation
CO2 narcosis was used to euthanize adult male mice (22–38 g).
Stomach was removed and 4–6 mm wide strips of smooth muscle
layer were prepared after shearing the mucosa. The strips were
transferred to a tissue bath with a Sylgard (Dow-Corning,
Midland, MI) floor and pinned to the floor with mucosal surface
facing up. The chamber was continuously perfused with warm
oxygenated (95% O2/5% CO2) Krebs solution at a rate of 3 ml/
min. The bath temperature was maintained at 3760.5uC and
entire set-up was protected from light.
Drugs and Chemicals
The drugs and chemicals were obtained from Sigma (St Louis,
MO) unless specified otherwise. They were prepared fresh before
use. DAF-2DA (Calbiochem, La Jolla, CA) and Calcium
Orange- acetoxymethyl ester (AM) (Molecular Probes, Eugene,
OR) and nifedipine were dissolved in dimethyl sulfoxide
(DMSO). The final bath concentration of chemicals were:
apamin (0.3 mM); atropine (1 mM ); calcium orange-AM
(10 mM); v-conotoxin-GVIA (vCTX) (0.1 mM); 4,5-diamino-
fluorescein diacetate (DAF-2DA) (10 mM); (100 mM); guanethi-
dine (5 mM); N-v-nitro-L-arginine methyl ester (L-NAME)
(200 mM); nifedipine (1 mM); tetrodotoxin (TTX) (1 mM); and
W7 (Calbiochem, La Jolla, CA) (100 mM).
Figure 4. Colocalization NO signals with nNOS immunoreactive
varicosities. In this experiment the muscle strip that was preloaded
with DAF-2 under NANC conditions, applied EFS and then fixed was
immunostained with anti-nNOS antibody. The NO signals are long
lasting as the reaction of NO with DAF-2 to form DAF-2T is irreversible.
Top panel shows imaging for NO and reveals spots of green
fluorescence, representing NO in the varicosities. Note that smooth
muscle cells showed no NO signals. The middle panel shows the same
section imaged for nNOS immunofluorescence. The bottom panel
shows the merged image revealing that the NO and nNOS signals are
superimposed indicating that NO was generated in the nNOS
immunoreactive nerves. Note that no NO signals were seen in
neighboring smooth muscle cells. (3206magnification).
doi:10.1371/journal.pone.0004990.g004
Table 1. Influence of various treatments on relative
quantification of NO and Ca
2+ signals.
Treatment NO signal Ca
2+ signal
Control 4.060.97 10.561.30
TTX 1.060.01 1.060.01
v-CTX GVIA 1.060.01 1.060.01
Nifedipine 4.761.50 9.762.00
W7 1.060.01 10.561.80
L-NAME 1.060.03 9.160.63
Values represent mean6SEM of normalized fluorescence intensity in arbitrary
units after EFS from three independent experiments.
doi:10.1371/journal.pone.0004990.t001
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Gastric muscle strips were mounted in a chamber and perfused
with Krebs’ solution prior to loading with dyes/drugs. Calcium
orange-AM and/or DAF-2A were added 1 hour prior to EFS.
The emission spectrum (576 nm) of Calcium orange can be well
resolved from that of DAF-2T (515 nm), thus facilitating
simultaneous imaging of the two components.
Electrical Field Stimulation
Tissues were incubated in fluorescent dyes for one hour prior to
EFS and antagonists were applied 20–30 min prior to the dye
loading. The EFS was applied under NANC conditions (in the
presence of atropine (1 mM) and guanethidine (5 mM)) to block
cholinergic and adrenergic responses to elicit nonadrenergic
noncholinergic inhibitory responses. The EFS consisted of 3
stimulus trains of 0.5 sec each (square wave pulses of 1 ms at
20 Hz, 70 volts) applied 30 seconds apart. The tissues were
immediately mounted on the slides and imaged promptly.
Imaging with multiphoton microscopy
Dye-loaded and treated tissues after EFS were imaged with
BioRad MRC 1024ES multi-photon imaging system (BioRad,
Hercules, CA). Theimaging systemwascoupled with a mode-locked
titanium:sapphire laser (Tsunami, Spectra-Physics, Mountain View,
CA) operating at 82 MHz repetition frequency, 80 fs pulse duration
with a wavelengthof 820 nm.Tri/sapphire lasertuned to820 nm in
multi-photon excitation mode at 700 mWwas able to excite calcium
orange-Ca
2+ (549 nm) and DAF-2T (495 nm) dyes to consistently
generate measurable emissions in orange-red (576 nm) and green
(515 nm)regions ofthe spectrum.The average laser power delivered
to the sample was 70–150 mW. Narrow band pass filters were used
to separate the emission spectra of the two dyes. A Zeiss Axiovert
S100 inverted microscope equipped with a high quality water
immersion 406/1.2 NA, C-apochroma objective was used in the
epifluorescence and/or transmission mode to image the nerve
varicosities. The 5126512 pixel images were collected in direct
detection configuration at a pixel resolution of 0.484 mmw i t ha
Kalman-5 collection filter. The nerve varicosities were identified by
Z scanning the circular smooth muscle layer and were generally at
depths of 150 mm. The images were reconstructed using the BioRad
LaserSharp software.
Relative quantification of Ca
2+ and NO signals
Impaired nitrergic neurotransmission may be associated with
reduced Ca
2+ response, normal Ca
2+ response but reduced NO
response or normal Ca
2+ and NO responses to EFS. We determined
the relative changes in calcium orange-Ca
2+ and DAF-NO
fluorescence, comparing the intensities of the signals in the
antagonist treated, EFS stimulated tissues with the unstimulated
control tissues.Three tosix boundaries weredrawn around arbitrary
areas along the nerve varicosities identified by XYZ scanning in a
field of view at 3206 magnification using an image processor
(LaserSharp, BioRad). Fluorescence intensity was integrated over all
pixels within the boundary of each individual enclosed area and
quantified using LaserSharp (BioRad) and MetaMorph (Universal
Imaging, West Chester, PA). The data are presented as the average
of at least three blinded experiments performed on different days.
Immunolabeling with anti-nNOS antibody
For colocalization of NO and nNOS, muscle strips were loaded
with the NO indicator, DAF-2DA and EFS applied as described
above. The tissues were then fixed in 4% freshly prepared
formaldehyde in PBS and were labeled with rabbit anti-nNOS
antibody.
Slow IJP Recordings
Intracellular membrane potential recordings under NANC
conditions were made using sharp microelectrodes with high
Figure 5. Effect of various antagonists on the slow IJPs in mice gastric muscle strips. The slow IJP was produced in response to EFS under
NANC conditions. Note that the slow IJP was suppressed by pretreatment with TTX and v-CTX GVIA but nifedipine had no effect (data not shown).
Moreover, calmodulin antagonist, W7 and nNOS inhibitor, L-NAME also blocked the slow IJP. Representative sIJPs are shown at the top of the bar of
the respective treatment groups.
doi:10.1371/journal.pone.0004990.g005
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publications [13,14,23].
Statistics
Data were expressed as means6SEM and appropriate tests
done to compare significance of difference in means (Student’s t
test and multiple comparisons, respectively).
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